世界の子宮がん治療薬市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2023 –2030 |
 市場規模（基準年） |
USD 2,412,036.20 Thousand |
 Market Size (Forecast Year) |
USD 4,269,049.34 Thousand |
 CAGR |
% |
| Major Markets Players |
|
>世界の子宮がん治療薬市場、がんの種類別（子宮内膜がんおよび子宮肉腫）、治療の種類別（化学療法、ホルモン療法、標的療法、免疫療法など）、薬剤の種類別（ジェネリックおよびブランド）、年齢層別（成人および高齢者）、投与経路別（経口および非経口）、エンドユーザー別（病院、がんセンター、専門クリニックなど）、流通チャネル別（直接入札、小売販売など） - 2030 年までの業界動向および予測。
子宮がん治療薬市場の分析と洞察
子宮がん治療薬の世界市場は、腫瘍学製薬業界全体にとって重要なセグメントであり、世界中で子宮がん患者が増加していることを反映しています。子宮がんは最も一般的な婦人科悪性腫瘍の 1 つであり、発症率は長年にわたって着実に上昇しています。この傾向には、人口の高齢化、肥満の蔓延、診断能力の向上による早期発見など、いくつかの要因が寄与しています。その結果、製薬会社がこの困難な病気に直面している患者のニーズに対応する革新的な治療法を開発するにつれて、子宮がん治療薬の市場は拡大し続けています。
世界の子宮がん治療薬市場を牽引する主な要因としては、研究開発の進歩、精密医療への重点の高まり、市場を牽引する分子メカニズムの理解の進展などが挙げられます。
しかし、市場は治療費の高騰、熟練した人材の不足、複雑な規制要件などの課題に直面しています。
世界の子宮がん治療薬市場は、2023年から2030年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に8.5％のCAGRで成長し、2022年の2,412,036.20千米ドルから2030年には4,269,049.34千米ドルに達すると分析しています。
子宮がん治療薬の世界市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されています。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームは、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、機械および医薬品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間中の市場の需要を推進した主な原動力です。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2015～2020年にカスタマイズ可能) |
|
定量単位 |
収益（千米ドル） |
|
対象セグメント |
がんの種類（子宮内膜がんおよび子宮肉腫）、治療の種類（化学療法、ホルモン療法、標的療法、免疫療法など）、薬剤の種類（ジェネリックおよびブランド）、年齢層（成人および高齢者）、投与経路（経口および非経口）、エンドユーザー（病院、がんセンター、専門クリニックなど）、流通チャネル（直接入札、小売販売など） |
|
対象国 |
米国、カナダ、メキシコ、ドイツ、フランス、英国、イタリア、スペイン、ロシア、トルコ、ベルギー、オランダ、スイス、その他のヨーロッパ諸国、中国、日本、インド、オーストラリア、韓国、ニュージーランド、シンガポール、タイ、フィリピン、マレーシア、インドネシア、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、サウジアラビア、UAE、南アフリカ、エジプト、カタール、クウェート、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
Baxter、Accord BioPharma、Inc.、Eli Lilly and Company、Hikma Pharmaceuticals PLC、Sun Pharmaceutical Industries Ltd.、Fresenius SE & Co. KGaA、Viatris Inc.、Sanofi、Teva Pharmaceuticals USA、Inc.、Amneal Pharmaceuticals LLC、Merck & Co.、Inc.、GSK plc.、エーザイ株式会社、Pfizer Inc.、Virtus、Getwell Oncology など。 |
世界の子宮がん治療薬市場の定義
子宮がん治療薬は、子宮内膜（子宮の内側の層）から発生する悪性腫瘍である子宮がんの治療と管理に特化した医薬品と治療法のクラスです。これらの薬は、子宮がんと診断された人の総合的な治療とケアにおいて重要な役割を果たします。その主な目的は、子宮内のがん細胞を標的とし、抑制または除去することで、病気の進行を遅らせたり停止させたりし、異常な子宮出血、骨盤痛、不快感などの関連症状を軽減することです。
世界の子宮がん治療薬市場の動向
ドライバー
- 世界中で子宮がんの発生率が上昇
近年、子宮がんの罹患率は世界中で著しく増加しており、世界的に重大な健康問題となっています。子宮がんの世界的な発症率の上昇は、遺伝、生活習慣、環境、医療の要因の組み合わせによって影響を受ける複雑かつ多面的な問題です。
例えば、
- 2023年3月、米国臨床腫瘍学会（ASCO）が発表した論文によると、子宮がんは米国で女性に最も多く見られるがんで4番目に多く、2020年には世界で推定417,367人が子宮がんと診断された。
したがって、世界的に子宮がんの発生率が上昇していることが市場の成長を牽引しています。
- 子宮がんの標的治療の進歩
子宮がんの標的療法の進歩は、治療結果の改善、副作用の軽減、患者の生活の質の向上に有望であることが示されています。標的療法は、従来の化学 療法のように急速に分裂する細胞に広く作用するのではなく、がん細胞の増殖と拡散に関与する特定の分子または経路に焦点を当てたがん治療の一種です。
標的療法は、がん細胞の特定の変化を標的にするように設計された薬剤です。高リスクまたは進行した子宮がんに有効です。
例えば、
レンバチニブ（レンビマ）はキナーゼ阻害剤です。腫瘍が新しい血管を形成するのを阻止します。また、がん細胞の増殖を助けるタンパク質を標的とします。医師はレンビマをキイトルーダと組み合わせて使用することがあります。レンビマは毎日服用する経口カプセルの形で提供されます。
したがって、子宮がんに対する標的療法の進歩が市場の成長を牽引しています。
機会
- ゲノムプロファイリングとバイオマーカー発見の進歩
ゲノムプロファイリングとバイオマーカーの発見の進歩は子宮がんの治療に大きな影響を与え、病気の管理に対してより的を絞った個別化されたアプローチを提供しています。子宮がんにはさまざまなサブタイプがありますが、これらの進歩により、各サブタイプに特有の遺伝子変異と分子特性が特定され、より効果的な治療戦略が可能になりました。
結論として、ゲノムプロファイリングとバイオマーカー発見の進歩は、子宮がん治療の状況を一変させました。これらの進歩により、子宮がんのサブタイプの遺伝的および分子的特性に関する理解が深まり、より的を絞った治療オプションと早期発見の可能性が生まれました。この分野の研究が進むにつれて、患者の転帰がさらに改善され、子宮がん患者が利用できる治療オプションの範囲が広がることが期待されます。したがって、ゲノムプロファイリングとバイオマーカー発見の進歩は、市場成長の機会として機能することが期待されます。
課題/制約
- 子宮がん治療の高額な費用
子宮がんは、手術、放射線療法、化学療法、標的療法、ホルモン療法など、さまざまな治療法を必要とすることがよくあります。これらのさまざまな治療法にかかる費用と、それに伴う入院、診察、経過観察の費用を合わせると、治療にかかる総費用が大幅に増加する可能性があります。子宮がんの患者は、手術、化学療法、放射線療法のために入院する必要があり、入院、手術室費用、入院治療に関連する費用が高額になることがあります。
そのため、子宮がん治療の高額な費用が市場の成長を妨げています。
- 市場における規制上のハードル
市場における規制上のハードルは、新しい治療法の開発、承認、およびアクセスを形作る重要な要素です。米国食品医薬品局 (FDA)、欧州医薬品庁 (EMA) などの規制機関は、医薬品の安全性、有効性、および品質の確保に責任を負っています。これらの機関は、医薬品開発プロセス中に企業が遵守しなければならない厳格な基準とガイドラインを定めています。
結論として、市場における規制上のハードルは多面的であり、長期化することもよくあります。
したがって、市場における規制上のハードルは、市場の成長に対する課題となることが予想されます。
最近の動向
- 2023年10月、メルク社は、シージェン社およびアステラス製薬と共同で実施した第3相KEYNOTE-A39試験（EV-302とも呼ばれる）の結果を発表しました。この試験では、国内で未治療の進行性または転移性尿路上皮がん患者を対象に、メルク社の抗PD-1療法であるKEYTRUDAと抗体薬物複合体であるPadcev（エンフォルツマブベドチン-EJFV）の併用と化学療法（ゲムシタビンとシスプラチンまたはカルボプラチンの併用）を比較しました。これにより、同社は自社ブランドKEYTRUDAの用途を拡大することができます。
- 2022年12月、サノフィとInnate Pharma SAは協力関係の拡大を発表し、サノフィはInnateのANKETTM（抗体ベースのNK細胞エンゲージャー治療薬）プラットフォームからB7H3を標的とするナチュラルキラー（NK）細胞エンゲージャープログラムのライセンスを取得しました。サノフィには、最大2つのANKETTMターゲットを追加するオプションもあります。候補が選定されると、サノフィはすべての開発、製造、商業化を担当します。この協力関係は、サノフィのオンコロジーポートフォリオを世界市場で拡大するのに役立ちます。
世界の子宮がん治療薬市場の範囲
世界の子宮がん治療薬市場は、がんの種類、治療の種類、薬の種類、年齢層、投与経路、エンドユーザー、流通チャネルに基づいて、5 つの主要なセグメントに分類されています。セグメント間の成長は、ニッチな成長分野と市場にアプローチするための戦略を分析し、コア アプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
がんの種類
- 子宮内膜がん
- 子宮肉腫
がんの種類に基づいて、市場は子宮内膜がんと子宮肉腫に分類されます。
治療の種類
- 化学療法
- 免疫療法
- ホルモン療法
- 標的療法
- その他
治療の種類に基づいて、市場は化学療法、免疫療法、ホルモン療法、標的療法などに分類されます。
薬剤の種類
- ジェネリック
- ブランド
医薬品の種類に基づいて、市場はジェネリック医薬品とブランド医薬品に分類されます。
年齢層
- 老年病
- 大人
年齢層に基づいて、市場は高齢者と成人に分割されます。
投与経路
- 非経口
- オーラル
投与経路に基づいて、市場は非経口と経口に分類されます。
エンドユーザー
- 病院
- がんセンター
- 専門クリニック
- その他
エンドユーザーに基づいて、市場は病院、がんセンター、専門クリニック、その他に分類されます。
流通チャネル
- 直接入札
- 小売販売
- その他
流通チャネルに基づいて、世界の子宮がん治療薬市場は、直接入札、小売販売、その他に分類されます。
地域分析/洞察: 世界の子宮がん治療薬市場
世界の子宮がん治療薬市場は、がんの種類、治療の種類、薬の種類、年齢層、投与経路、エンドユーザー、流通チャネルなど、7 つの主要なセグメントに分類されています。
この市場レポートでカバーされている国は、米国、カナダ、メキシコ、ドイツ、フランス、英国、イタリア、スペイン、ロシア、トルコ、ベルギー、オランダ、スイス、その他のヨーロッパ諸国、中国、日本、インド、オーストラリア、韓国、ニュージーランド、シンガポール、タイ、フィリピン、マレーシア、インドネシア、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、サウジアラビア、UAE、南アフリカ、エジプト、カタール、クウェート、その他の中東およびアフリカ諸国です。
子宮がん治療薬市場における技術進歩の高まりにより、米国は北米地域を支配すると予想されています。ドイツは、主要企業の強力な存在により、ヨーロッパ地域を支配すると予想されています。中国は、子宮がん治療薬ベースの製品の大量生産と新興市場からの需要の増加と拡大により、アジア太平洋地域を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
競争環境とシェア分析: 世界の子宮がん治療薬市場
世界の子宮がん治療薬市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、製品タイプのライフライン曲線が含まれます。提供されている上記のデータ ポイントは、会社の世界の子宮がん治療薬市場への焦点にのみ関連しています。
世界の子宮がん治療薬市場で活動している主要企業としては、バクスター、アコード・バイオファーマ、イーライリリー、ヒクマ・ファーマシューティカルズ、サン・ファーマシューティカル・インダストリーズ、フレゼニウス SE & Co. KGaA、ビアトリス、サノフィ、テバ・ファーマシューティカルズ USA、アムニール・ファーマシューティカルズ LLC、メルク、GSK、エーザイ、ファイザー、ヴァータス、ゲットウェル・オンコロジーなどが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CANCER TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
5 GLOBAL UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK
5.1 OVERVIEW
5.2 REGULATION IN THE U.S.
5.3 REGULATION IN CANADA
5.4 REGULATION IN EUROPE
5.5 REGULATION IN CHINA
5.6 REGULATION IN JAPAN
5.7 REGULATION IN AUSTRALIA
5.8 REGULATION IN INDIA
5.9 REGULATION IN BRAZIL
5.1 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE
6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER
6.1.3 RISING AWARENESS OF UTERINE CANCER
6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF UTERINE CANCER TREATMENT
6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY
6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT
6.4 CHALLENGES
6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET
6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER
7 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE
7.1 OVERVIEW
7.2 ENDOMETRIAL CANCER
7.2.1 UTERINE CARCINOSARCOMA
7.2.2 SEROUS ADENOSARCOMA
7.2.3 ADENOSQUAMOUS CARCINOMA
7.2.4 OTHER
7.3 UTERINE SARCOMA
7.3.1 UTERINE LEIOMYOSARCOMA
7.3.2 ENDOMETRIAL STROMAL SARCOMAS
7.3.3 UNDIFFERENTIATED SARCOMA
8 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 CHEMOTHERAPY
8.2.1 PACLITAXEL
8.2.2 CARBOPLATIN
8.2.3 CISPLATIN
8.2.4 DOXORUBICIN
8.2.5 DOCETAXEL
8.2.6 OTHERS
8.3 IMMUNOTHERAPY
8.4 HORMONE THERAPY
8.4.1 PROGESTINS
8.4.1.1 MEDROXYPROGESTERONE ACETATE
8.4.1.2 OTHERS
8.4.2 AROMATASE INHIBITORS
8.4.2.1 LETRAZOLE
8.4.2.2 ANASTRAZOLE
8.4.2.3 EXEMESTANE
8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS
8.4.3.1 GOSERELIN
8.4.3.2 LEUPROLIDE
8.4.4 OTHERS
8.5 TARGETED THERAPY
8.5.1 LENVATINAB
8.5.2 BEVACIZUMAB
8.5.3 MTOR INHIBITORS
8.5.3.1 EVEROLIMUS
8.5.3.2 TEMSIROLIMUS
8.6 OTHERS
9 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 KEYTRUDA
9.3.2 LENVIMA
9.3.3 PROVERA
9.3.4 TEMODAR
9.3.5 JEMPERLI
9.3.6 OTHERS
10 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 GERIATRIC
10.3 ADULTS
11 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 PARENTERAL
11.3 ORAL
12 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PRIVATE
12.2.2 PUBLIC
12.3 CANCER CENTERS
12.4 SPECIALTY CLINICS
12.5 OTHERS
13 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
13.4 OTHERS
14 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 U.K.
14.3.3 FRANCE
14.3.4 RUSSIA
14.3.5 ITALY
14.3.6 SPAIN
14.3.7 TURKEY
14.3.8 BELGIUM
14.3.9 NETHERLANDS
14.3.10 SWITZERLAND
14.3.11 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 CHINA
14.4.2 JAPAN
14.4.3 INDIA
14.4.4 AUSTRALIA
14.4.5 SOUTH KOREA
14.4.6 NEW ZEALAND
14.4.7 SINGAPORE
14.4.8 THAILAND
14.4.9 MALAYSIA
14.4.10 INDONESIA
14.4.11 PHILIPPINES
14.4.12 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SAUDI ARABIA
14.6.2 U.A.E.
14.6.3 SOUTH AFRICA
14.6.4 EGYPT
14.6.5 KUWAIT
14.6.6 REST OF MIDDLE EAST AFRICA
15 GLOBAL UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 MERCK & CO., INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 EISAI CO., LTD.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.2.6 RECENT DEVELOPMENT
17.3 SANOFI
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 PFIZER INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 TEVA PHARMACEUTICALS USA, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ACCORD HEALTHCARE US.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 AMNEAL PHARMACEUTICALS LLC
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BAXTER
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 COMPANY SHARE ANALYSIS
17.8.4 PRODUCT PORTFOLIO
17.8.5 RECENT DEVELOPMENT
17.9 ELI LILLY AND COMPANY
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.1 GETWELL ONCOLOGY
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 GSK PLC.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 HIKMA PHARMACEUTICALS PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 VIATRIS INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 VIRTUS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND)
TABLE 2 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 GLOBAL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 GLOBAL IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 10 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 11 GLOBAL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 GLOBAL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 GLOBAL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 GLOBAL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 16 GLOBAL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 GLOBAL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 19 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 20 GLOBAL GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 22 GLOBAL BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND)
TABLE 24 GLOBAL GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 25 GLOBAL ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 GLOBAL PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 GLOBAL ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 29 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND)
TABLE 30 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 31 GLOBAL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 32 GLOBAL CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 33 GLOBAL SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 34 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND)
TABLE 36 GLOBAL DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 37 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 GLOBAL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 GLOBAL OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 42 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 NORTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 47 NORTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 NORTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 49 NORTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 50 NORTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 51 NORTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 NORTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 53 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 NORTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 55 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 56 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 57 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 58 NORTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 NORTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 60 NORTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.S. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.S. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.S. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 U.S. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 66 U.S. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.S. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 68 U.S. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 69 U.S. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 70 U.S. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 U.S. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 72 U.S. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 U.S. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 74 U.S. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 75 U.S. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 76 U.S. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 77 U.S. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 U.S. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 79 U.S. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 CANADA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 CANADA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 CANADA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 CANADA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 85 CANADA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 CANADA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 87 CANADA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 88 CANADA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 89 CANADA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 CANADA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 91 CANADA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 CANADA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 93 CANADA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 94 CANADA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 95 CANADA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 96 CANADA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 CANADA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 98 CANADA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 MEXICO UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 MEXICO UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 MEXICO UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 MEXICO CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 104 MEXICO HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 MEXICO PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 106 MEXICO AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 107 MEXICO LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 108 MEXICO TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 MEXICO MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 110 MEXICO UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 MEXICO BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 112 MEXICO UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 113 MEXICO UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 114 MEXICO UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 115 MEXICO HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 MEXICO UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 117 MEXICO RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 119 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 122 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 124 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 126 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 127 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 128 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 130 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 132 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 133 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 134 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 135 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 137 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 143 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 145 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 146 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 147 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 149 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 151 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 152 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 153 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 154 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 156 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 162 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 164 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 165 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 166 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 168 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 170 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 171 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 172 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 173 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 175 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 181 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 183 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 184 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 185 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 186 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 187 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 189 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 190 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 191 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 192 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 194 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 200 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 202 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 203 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 204 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 206 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 208 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 209 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 210 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 211 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 213 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 217 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 219 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 221 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 222 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 223 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 224 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 225 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 227 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 228 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 229 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 230 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 232 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 236 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 238 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 240 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 241 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 242 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 244 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 246 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 247 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 248 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 249 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 251 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 255 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 257 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 259 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 260 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 261 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 262 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 263 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 265 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 266 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 267 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 268 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 270 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 274 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 276 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 278 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 279 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 280 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 281 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 282 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 284 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 285 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 286 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 287 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 289 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 293 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 295 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 297 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 298 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 299 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 300 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 301 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 303 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 304 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 305 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 306 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 307 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 308 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 309 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 313 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 314 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 315 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 316 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 317 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 318 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 319 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 320 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 321 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 322 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 323 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 324 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 325 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 327 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 328 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 329 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 330 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 331 ASIA-PACIFIC ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 332 ASIA-PACIFIC UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 333 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 334 ASIA-PACIFIC CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 335 ASIA-PACIFIC HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 336 ASIA-PACIFIC PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 337 ASIA-PACIFIC AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 338 ASIA-PACIFIC LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 339 ASIA-PACIFIC TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 340 ASIA-PACIFIC MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 341 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 342 ASIA-PACIFIC BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 343 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 344 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 345 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 346 ASIA-PACIFIC HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 347 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 348 ASIA-PACIFIC RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 349 CHINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 350 CHINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 351 CHINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 352 CHINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 353 CHINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 354 CHINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 355 CHINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 356 CHINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 357 CHINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 358 CHINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 359 CHINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 360 CHINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 361 CHINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 362 CHINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 363 CHINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 364 CHINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 365 CHINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 366 CHINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 367 CHINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 368 JAPAN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 369 JAPAN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 370 JAPAN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 371 JAPAN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 372 JAPAN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 373 JAPAN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 374 JAPAN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 375 JAPAN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 376 JAPAN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 377 JAPAN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 378 JAPAN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 379 JAPAN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 380 JAPAN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 381 JAPAN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 382 JAPAN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 383 JAPAN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 384 JAPAN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 385 JAPAN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 386 JAPAN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 387 INDIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 388 INDIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 389 INDIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 390 INDIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 391 INDIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 392 INDIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 393 INDIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 394 INDIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 395 INDIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 396 INDIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 397 INDIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 398 INDIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 399 INDIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 400 INDIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 401 INDIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 402 INDIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 403 INDIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 404 INDIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 405 INDIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 406 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 407 AUSTRALIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 408 AUSTRALIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 409 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 410 AUSTRALIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 411 AUSTRALIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 412 AUSTRALIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 413 AUSTRALIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 414 AUSTRALIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 415 AUSTRALIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 416 AUSTRALIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 417 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 418 AUSTRALIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 419 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 420 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 421 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 422 AUSTRALIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 423 AUSTRALIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 424 AUSTRALIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 425 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 426 SOUTH KOREA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 427 SOUTH KOREA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 428 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 429 SOUTH KOREA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 430 SOUTH KOREA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 431 SOUTH KOREA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 432 SOUTH KOREA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 433 SOUTH KOREA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 434 SOUTH KOREA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 435 SOUTH KOREA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 436 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 437 SOUTH KOREA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 438 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 439 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 440 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 441 SOUTH KOREA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 442 SOUTH KOREA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 443 SOUTH KOREA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 444 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 445 NEW ZEALAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 446 NEW ZEALAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 447 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 448 NEW ZEALAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 449 NEW ZEALAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 450 NEW ZEALAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 451 NEW ZEALAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 452 NEW ZEALAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 453 NEW ZEALAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 454 NEW ZEALAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 455 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 456 NEW ZEALAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 457 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 458 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 459 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 460 NEW ZEALAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 461 NEW ZEALAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 462 NEW ZEALAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 463 SINGAPORE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 464 SINGAPORE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 465 SINGAPORE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 466 SINGAPORE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 467 SINGAPORE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 468 SINGAPORE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 469 SINGAPORE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 470 SINGAPORE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 471 SINGAPORE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 472 SINGAPORE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 473 SINGAPORE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 474 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 475 SINGAPORE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 476 SINGAPORE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 477 SINGAPORE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 478 SINGAPORE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 479 SINGAPORE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 480 SINGAPORE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 481 SINGAPORE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 482 THAILAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 483 THAILAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 484 THAILAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 485 THAILAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 486 THAILAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 487 THAILAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 488 THAILAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 489 THAILAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 490 THAILAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 491 THAILAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 492 THAILAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 493 THAILAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 494 THAILAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 495 THAILAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 496 THAILAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 497 THAILAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 498 THAILAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 499 THAILAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 500 THAILAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 501 MALAYSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 502 MALAYSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 503 MALAYSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 504 MALAYSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 505 MALAYSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 506 MALAYSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 507 MALAYSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 508 MALAYSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 509 MALAYSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 510 MALAYSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 511 MALAYSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 512 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 513 MALAYSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 514 MALAYSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 515 MALAYSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 516 MALAYSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 517 MALAYSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 518 MALAYSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 519 MALAYSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 520 INDONESIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 521 INDONESIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 522 INDONESIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 523 INDONESIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 524 INDONESIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 525 INDONESIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 526 INDONESIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 527 INDONESIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 528 INDONESIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 529 INDONESIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 530 INDONESIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 531 INDONESIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 532 INDONESIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 533 INDONESIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 534 INDONESIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 535 INDONESIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 536 INDONESIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 537 INDONESIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 538 INDONESIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 539 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 540 PHILIPPINES ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 541 PHILIPPINES UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 542 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 543 PHILIPPINES CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 544 PHILIPPINES HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 545 PHILIPPINES PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 546 PHILIPPINES AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 547 PHILIPPINES LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 548 PHILIPPINES TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 549 PHILIPPINES MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 550 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 551 PHILIPPINES BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 552 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 553 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 554 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 555 PHILIPPINES HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 556 PHILIPPINES UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 557 PHILIPPINES RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 558 REST OF ASIA-PACIFIC UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 559 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 560 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 561 SOUTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 562 SOUTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 563 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 564 SOUTH AMERICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 565 SOUTH AMERICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 566 SOUTH AMERICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 567 SOUTH AMERICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 568 SOUTH AMERICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 569 SOUTH AMERICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 570 SOUTH AMERICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 571 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 572 SOUTH AMERICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 573 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 574 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 575 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 576 SOUTH AMERICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 577 SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 578 SOUTH AMERICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 579 BRAZIL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 580 BRAZIL ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 581 BRAZIL UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 582 BRAZIL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 583 BRAZIL CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 584 BRAZIL HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 585 BRAZIL PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 586 BRAZIL AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 587 BRAZIL LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 588 BRAZIL TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 589 BRAZIL MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 590 BRAZIL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 591 BRAZIL BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 592 BRAZIL UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 593 BRAZIL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 594 BRAZIL UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 595 BRAZIL HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 596 BRAZIL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 597 BRAZIL RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 598 ARGENTINA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 599 ARGENTINA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 600 ARGENTINA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 601 ARGENTINA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 602 ARGENTINA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 603 ARGENTINA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 604 ARGENTINA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 605 ARGENTINA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 606 ARGENTINA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 607 ARGENTINA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 608 ARGENTINA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 609 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 610 ARGENTINA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 611 ARGENTINA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 612 ARGENTINA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 613 ARGENTINA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 614 ARGENTINA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 615 ARGENTINA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 616 ARGENTINA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 617 REST OF SOUTH AMERICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 618 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 619 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 620 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 621 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 622 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 623 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 624 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 625 MIDDLE EAST AND AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 626 MIDDLE EAST AND AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 627 MIDDLE EAST AND AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 628 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 629 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 630 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 631 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 632 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 633 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 634 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 635 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 636 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 637 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 638 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 639 SAUDI ARABIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 640 SAUDI ARABIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 641 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 642 SAUDI ARABIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 643 SAUDI ARABIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 644 SAUDI ARABIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 645 SAUDI ARABIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 646 SAUDI ARABIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 647 SAUDI ARABIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 648 SAUDI ARABIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 649 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 650 SAUDI ARABIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 651 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 652 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 653 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 654 SAUDI ARABIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 655 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 656 SAUDI ARABIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 657 U.A.E. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 658 U.A.E. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 659 U.A.E. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 660 U.A.E. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 661 U.A.E. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 662 U.A.E. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 663 U.A.E. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 664 U.A.E. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 665 U.A.E. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 666 U.A.E. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 667 U.A.E. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 668 U.A.E. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 669 U.A.E. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 670 U.A.E. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 671 U.A.E. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 672 U.A.E. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 673 U.A.E. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 674 U.A.E. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 675 U.A.E. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 676 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 677 SOUTH AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 678 SOUTH AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 679 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 680 SOUTH AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 681 SOUTH AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 682 SOUTH AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 683 SOUTH AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 684 SOUTH AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 685 SOUTH AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 686 SOUTH AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 687 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 688 SOUTH AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 689 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 690 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 691 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 692 SOUTH AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 693 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 694 SOUTH AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 695 EGYPT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 696 EGYPT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 697 EGYPT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 698 EGYPT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 699 EGYPT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 700 EGYPT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 701 EGYPT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 702 EGYPT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 703 EGYPT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 704 EGYPT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 705 EGYPT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 706 EGYPT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 707 EGYPT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 708 GYPT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 709 EGYPT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 710 EGYPT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 711 EGYPT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 712 EGYPT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 713 EGYPT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 714 KUWAIT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 715 KUWAIT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 716 KUWAIT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 717 KUWAIT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 718 KUWAIT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 719 KUWAIT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 720 KUWAIT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 721 KUWAIT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 722 KUWAIT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 723 KUWAIT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 724 KUWAIT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 725 KUWAIT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 726 KUWAIT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 727 KUWAIT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 728 KUWAIT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 729 KUWAIT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 730 KUWAIT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 731 KUWAIT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 732 KUWAIT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 733 REST OF MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
図表一覧
FIGURE 1 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 GLOBAL UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL UTERINE CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL UTERINE CANCER DRUGS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030
FIGURE 13 NORTH AMEIRCA IS EXPECTED TO DOMINATE THE GLOBAL UTERINE CANCER DRUGS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR UTERINE CANCER DRUG MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL UTERINE CANCER DRUGS MARKET
FIGURE 16 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022
FIGURE 17 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND)
FIGURE 18 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 19 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022
FIGURE 21 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 22 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 23 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 25 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 26 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 27 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 GLOBAL UTERINE CANCER DRUGS MARKET: BY TYPE, 2022
FIGURE 29 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND)
FIGURE 30 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 31 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 32 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 33 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 34 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 35 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2022
FIGURE 37 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 38 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 39 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 41 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 42 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 43 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 GLOBAL UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022)
FIGURE 45 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 46 NORTH AMERICA UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 47 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 48 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
